-$0.41 Earnings Per Share Expected for Minerva Neurosciences Inc (NASDAQ:NERV) This Quarter

Share on StockTwits

Brokerages expect Minerva Neurosciences Inc (NASDAQ:NERV) to report earnings of ($0.41) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Minerva Neurosciences’ earnings, with the lowest EPS estimate coming in at ($0.49) and the highest estimate coming in at ($0.36). Minerva Neurosciences posted earnings per share of ($0.34) during the same quarter last year, which would indicate a negative year over year growth rate of 20.6%. The company is scheduled to report its next earnings report on Tuesday, March 10th.

On average, analysts expect that Minerva Neurosciences will report full-year earnings of ($1.48) per share for the current financial year, with EPS estimates ranging from ($1.58) to ($1.44). For the next fiscal year, analysts expect that the company will report earnings of ($1.69) per share, with EPS estimates ranging from ($3.32) to ($0.91). Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that follow Minerva Neurosciences.

A number of equities analysts have recently commented on NERV shares. William Blair reissued a “buy” rating on shares of Minerva Neurosciences in a research report on Friday, February 7th. Zacks Investment Research lowered shares of Minerva Neurosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, October 29th. Chardan Capital reissued a “buy” rating on shares of Minerva Neurosciences in a research report on Monday, December 2nd. ValuEngine downgraded shares of Minerva Neurosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, January 28th. Finally, JMP Securities lowered their price objective on shares of Minerva Neurosciences from $20.00 to $18.00 and set a “market outperform” rating on the stock in a research note on Thursday, December 19th. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $17.15.

In other news, CFO Geoff Race sold 5,826 shares of the firm’s stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $7.10, for a total value of $41,364.60. Following the sale, the chief financial officer now owns 210,870 shares in the company, valued at $1,497,177. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In the last 90 days, insiders sold 12,519 shares of company stock worth $88,885. 12.00% of the stock is currently owned by corporate insiders.

Institutional investors have recently made changes to their positions in the company. Bank of Montreal Can boosted its stake in Minerva Neurosciences by 45.2% during the fourth quarter. Bank of Montreal Can now owns 3,767 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,173 shares in the last quarter. Blair William & Co. IL boosted its stake in Minerva Neurosciences by 6.6% during the fourth quarter. Blair William & Co. IL now owns 25,100 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 1,550 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Minerva Neurosciences by 4.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 72,990 shares of the biopharmaceutical company’s stock worth $519,000 after buying an additional 3,184 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Minerva Neurosciences during the third quarter worth $35,000. Finally, Raymond James Financial Services Advisors Inc. boosted its stake in Minerva Neurosciences by 20.0% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 30,000 shares of the biopharmaceutical company’s stock worth $213,000 after buying an additional 5,000 shares in the last quarter. Institutional investors and hedge funds own 81.69% of the company’s stock.

Shares of NASDAQ:NERV traded down $0.07 during trading on Friday, reaching $8.93. The stock had a trading volume of 187,900 shares, compared to its average volume of 313,191. Minerva Neurosciences has a 52 week low of $4.01 and a 52 week high of $9.56. The firm has a market capitalization of $360.20 million, a price-to-earnings ratio of -6.24 and a beta of 1.51. The stock has a fifty day simple moving average of $8.26 and a two-hundred day simple moving average of $6.76.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.

Recommended Story: Closed-End Mutual Funds

Get a free copy of the Zacks research report on Minerva Neurosciences (NERV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.